Characteristics and Long-Term Outcome of Neurosarcoidosis: A Population-Based Study from 1976-2013

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: Neurosarcoidosis is a rare condition with serious health consequences. However, little is known about clinical characteristics and outcome of neurosarcoidosis in the community setting. Methods: Patients with neurosarcoidosis were identified from a previously described cohort of patients with incident sarcoidosis from Olmsted County, Minnesota, United States from 1976 to 2013 using individual medical record review. Data on clinical characteristics, treatment, and outcome were collected. Results: Neurological involvement by sarcoidosis occurred in 11 patients (3% of all patients with sarcoidosis). Cranial neuropathy was the most common type of neurological disease (5 patients; 45%) followed by peripheral neuropathy (3 patients; 27%), and meningitis (3 patients; 27%). Cerebrospinal fluid (CSF) pleocytosis and elevated CSF protein levels were observed in patients with meningitis, intramedullary spinal cord sarcoidosis, intracranial mass lesion and some patients with cranial neuropathy but were normal in patients with peripheral neuropathy. All patients received high-dose glucocorticoids as initial treatment and almost all responded to this therapy. Relapse after glucocorticoid dose reduction necessitated subsequent treatment with steroid-sparing agents in 4 patients. Conclusion: Neurosarcoidosis is an uncommon manifestation of sarcoidosis. Neurosarcoidosis manifestations generally responded well to high-dose glucocorticoids in the majority of patients, but relapse was common.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalNeuroepidemiology
Volume48
Issue number3-4
DOIs
StatePublished - Aug 1 2017

Fingerprint

Population
Sarcoidosis
Glucocorticoids
Cranial Nerve Diseases
Peripheral Nervous System Diseases
Meningitis
Neurosarcoidosis
Cerebrospinal Fluid Proteins
Recurrence
Leukocytosis
Medical Records
Cerebrospinal Fluid
Spinal Cord
Therapeutics
Steroids
Health

Keywords

  • Epidemiology
  • Neurosarcoidosis
  • Outcome
  • Sarcoidosis

ASJC Scopus subject areas

  • Epidemiology
  • Clinical Neurology

Cite this

Characteristics and Long-Term Outcome of Neurosarcoidosis : A Population-Based Study from 1976-2013. / Ungprasert, Patompong; Crowson, Cynthia; Matteson, Eric Lawrence.

In: Neuroepidemiology, Vol. 48, No. 3-4, 01.08.2017, p. 87-94.

Research output: Contribution to journalArticle

@article{519e869e93f14e3188f943026b26eb71,
title = "Characteristics and Long-Term Outcome of Neurosarcoidosis: A Population-Based Study from 1976-2013",
abstract = "Background/Aims: Neurosarcoidosis is a rare condition with serious health consequences. However, little is known about clinical characteristics and outcome of neurosarcoidosis in the community setting. Methods: Patients with neurosarcoidosis were identified from a previously described cohort of patients with incident sarcoidosis from Olmsted County, Minnesota, United States from 1976 to 2013 using individual medical record review. Data on clinical characteristics, treatment, and outcome were collected. Results: Neurological involvement by sarcoidosis occurred in 11 patients (3{\%} of all patients with sarcoidosis). Cranial neuropathy was the most common type of neurological disease (5 patients; 45{\%}) followed by peripheral neuropathy (3 patients; 27{\%}), and meningitis (3 patients; 27{\%}). Cerebrospinal fluid (CSF) pleocytosis and elevated CSF protein levels were observed in patients with meningitis, intramedullary spinal cord sarcoidosis, intracranial mass lesion and some patients with cranial neuropathy but were normal in patients with peripheral neuropathy. All patients received high-dose glucocorticoids as initial treatment and almost all responded to this therapy. Relapse after glucocorticoid dose reduction necessitated subsequent treatment with steroid-sparing agents in 4 patients. Conclusion: Neurosarcoidosis is an uncommon manifestation of sarcoidosis. Neurosarcoidosis manifestations generally responded well to high-dose glucocorticoids in the majority of patients, but relapse was common.",
keywords = "Epidemiology, Neurosarcoidosis, Outcome, Sarcoidosis",
author = "Patompong Ungprasert and Cynthia Crowson and Matteson, {Eric Lawrence}",
year = "2017",
month = "8",
day = "1",
doi = "10.1159/000477300",
language = "English (US)",
volume = "48",
pages = "87--94",
journal = "Neuroepidemiology",
issn = "0251-5350",
publisher = "S. Karger AG",
number = "3-4",

}

TY - JOUR

T1 - Characteristics and Long-Term Outcome of Neurosarcoidosis

T2 - A Population-Based Study from 1976-2013

AU - Ungprasert, Patompong

AU - Crowson, Cynthia

AU - Matteson, Eric Lawrence

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background/Aims: Neurosarcoidosis is a rare condition with serious health consequences. However, little is known about clinical characteristics and outcome of neurosarcoidosis in the community setting. Methods: Patients with neurosarcoidosis were identified from a previously described cohort of patients with incident sarcoidosis from Olmsted County, Minnesota, United States from 1976 to 2013 using individual medical record review. Data on clinical characteristics, treatment, and outcome were collected. Results: Neurological involvement by sarcoidosis occurred in 11 patients (3% of all patients with sarcoidosis). Cranial neuropathy was the most common type of neurological disease (5 patients; 45%) followed by peripheral neuropathy (3 patients; 27%), and meningitis (3 patients; 27%). Cerebrospinal fluid (CSF) pleocytosis and elevated CSF protein levels were observed in patients with meningitis, intramedullary spinal cord sarcoidosis, intracranial mass lesion and some patients with cranial neuropathy but were normal in patients with peripheral neuropathy. All patients received high-dose glucocorticoids as initial treatment and almost all responded to this therapy. Relapse after glucocorticoid dose reduction necessitated subsequent treatment with steroid-sparing agents in 4 patients. Conclusion: Neurosarcoidosis is an uncommon manifestation of sarcoidosis. Neurosarcoidosis manifestations generally responded well to high-dose glucocorticoids in the majority of patients, but relapse was common.

AB - Background/Aims: Neurosarcoidosis is a rare condition with serious health consequences. However, little is known about clinical characteristics and outcome of neurosarcoidosis in the community setting. Methods: Patients with neurosarcoidosis were identified from a previously described cohort of patients with incident sarcoidosis from Olmsted County, Minnesota, United States from 1976 to 2013 using individual medical record review. Data on clinical characteristics, treatment, and outcome were collected. Results: Neurological involvement by sarcoidosis occurred in 11 patients (3% of all patients with sarcoidosis). Cranial neuropathy was the most common type of neurological disease (5 patients; 45%) followed by peripheral neuropathy (3 patients; 27%), and meningitis (3 patients; 27%). Cerebrospinal fluid (CSF) pleocytosis and elevated CSF protein levels were observed in patients with meningitis, intramedullary spinal cord sarcoidosis, intracranial mass lesion and some patients with cranial neuropathy but were normal in patients with peripheral neuropathy. All patients received high-dose glucocorticoids as initial treatment and almost all responded to this therapy. Relapse after glucocorticoid dose reduction necessitated subsequent treatment with steroid-sparing agents in 4 patients. Conclusion: Neurosarcoidosis is an uncommon manifestation of sarcoidosis. Neurosarcoidosis manifestations generally responded well to high-dose glucocorticoids in the majority of patients, but relapse was common.

KW - Epidemiology

KW - Neurosarcoidosis

KW - Outcome

KW - Sarcoidosis

UR - http://www.scopus.com/inward/record.url?scp=85028666470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028666470&partnerID=8YFLogxK

U2 - 10.1159/000477300

DO - 10.1159/000477300

M3 - Article

C2 - 28601860

AN - SCOPUS:85028666470

VL - 48

SP - 87

EP - 94

JO - Neuroepidemiology

JF - Neuroepidemiology

SN - 0251-5350

IS - 3-4

ER -